Celyad Oncology SA announced that on March 1, 2022, the company was informed via e-mail communication from the U.S. Food and Drug Administration that the CYAD-101-002 (KEYNOTE-B79) Phase 1b trial has been placed on clinical hold due to insufficient information to assess risk to study subjects. As previously disclosed, on February 28, 2022, the company announced that it was voluntarily pausing the CYAD-101-002 trial to investigate reports of two fatalities in the study.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.32 EUR | -3.03% | -5.74% | -17.95% |
Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-17.95% | 14.63M | |
+4.09% | 43.43B | |
+47.81% | 41.69B | |
+9.45% | 41.31B | |
-10.92% | 27.14B | |
+9.32% | 25.28B | |
-24.87% | 18.47B | |
+29.70% | 12.59B | |
+1.28% | 12.33B | |
+7.78% | 11.03B |
- Stock Market
- Equities
- CYAD Stock
- News Celyad Oncology SA
- Celyad Oncology Announces Clinical Hold of CYAD-101-002 Phase 1b Trial